^
BIOMARKER:

IDH2 mutation

i
Other names: IDH2, Isocitrate Dehydrogenase (NADP(+)) 2, Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial, Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial, Isocitrate Dehydrogenase [NADP], Mitochondrial, Oxalosuccinate Decarboxylase, NADP(+)-Specific ICDH, ICD-M, IDH, IDP, MNADP-IDH, D2HGA2, IDHM, IDPM




Show legend

Include preclinical:
Acute Myelogenous Leukemia
Astrocytoma
Glioma
Glioblastoma
Cholangiocarcinoma
Sarcoma
Anaplastic Astrocytoma
Lymphoma
Acute Lymphocytic Leukemia
Chronic Myelomonocytic Leukemia
Peripheral T-cell Lymphoma
Myelodysplastic Syndrome
Oligodendroglioma
Hematological Malignancies
Leukemia
T Cell Non-Hodgkin Lymphoma
7+3 (DAC)
PCV
IDH1 inhibitor
DCAG
CDIAG
venetoclax
etoposide IV
bevacizumab
lomustine
carmustine
cisplatin
carboplatin
S95032
temozolomide gel
temozolomide
enasidenib
venetoclax + enasidenib
olaparib
cytarabine + clofarabine
cytarabine + cladribine
decitabine + clofarabine
decitabine + cladribine
M7824
pamiparib
dasatinib
MEN1703
cytarabine/daunorubicin liposomal formulation
venetoclax + RG7388
copanlisib
TG02
venetoclax + ABBV-621
CFI-400945
AV-GBM-1
ivosidenib
TQB3455
venetoclax + ivosidenib
venetoclax + enasidenib + decitabine/cedazuridine
gemtuzumab ozogamicin
PRT811
azacitidine + romidepsin
paclitaxel
cytarabine
decitabine
venetoclax + gilteritinib
AZD0530
bosutinib
ponatinib
APO866
venetoclax + midostaurin
NPI-0052
omacetaxine mepesuccinate
lenalidomide
venetoclax + sorafenib
regorafenib
dactinomycin
romidepsin
daunorubicin
teniposide
gemcitabine